PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Gris-Oliver A, Ibrahim YH, Rivas MA, Garcia-Garcia C, et al. Br J Cancer 2021 Mar 15. pii: 10.1038/s41416-021-01293.

Read + Share

Amedeo Smart

Independent Medical Education

Gris-Oliver A, Ibrahim YH, Rivas MA, Garcia-Garcia C, et al. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer 2021 Mar 15. pii: 10.1038/s41416-021-01293.
PMID: 33723394